Roflumilast Foam Shows Promise in Reducing Itch and Improving Quality of Life for Psoriasis Patients
Key Insights
Roflumilast foam 0.3% demonstrated significant reduction in scalp and overall body itch in psoriasis (search) patients after 8 weeks in the ARRECTOR trial.
The once-daily, non-steroidal PDE4 (search) inhibitor showed a favorable tolerability profile, with minimal irritation reported by both investigators and patients.
Approximately 66% of patients achieved Investigator's Global Assessment (IGA) success in scalp psoriasis (search), with 40% achieving a clear scalp.
Roflumilast foam 0.3% has shown promising results in alleviating itch and enhancing the quality of life for individuals suffering from psoriasis (search), according to findings presented at the 44th Annual Fall Clinical Dermatology Conference. The ARRECTOR trial, a vehicle-controlled, double-blind study, assessed the safety and efficacy of roflumilast foam in patients with psoriasis.
Key Findings from the ARRECTOR Trial
The study revealed that over 50% of patients experienced a significant reduction in itch, achieving a score of 0 or 1 on the Worst Itch NRS and Scalp Itch NRS, indicating no or minimal itch on the scalp or overall body after eight weeks of roflumilast foam use. Melinda Gooderham, MD, MSc, a dermatologist at the SKiN Centre for Dermatology (search) in Ontario, highlighted the patient-reported outcomes data from the trial.
Addressing Unmet Needs in Psoriasis Treatment
Dr. Gooderham emphasized that roflumilast foam addresses several unmet needs in psoriasis (search) treatment by offering a convenient once-a-day application. "I think this roflumilast foam will really address the unmet needs by, number 1, providing a convenient once-a-day application," she stated. She noted that adherence can be a challenge for many patients using topical therapies, and the ease of use, non-greasy formulation, and good tolerability of roflumilast foam can improve patient compliance.
Tolerability and Efficacy
The medication demonstrated excellent tolerability, with investigators reporting no irritation. Patients also reported high tolerability, with an average score of 0.5 on the patient-related tolerability scale (0 = no sensation, 1 = mild sensation), indicating that most patients experienced no significant issues tolerating the medication.
In terms of efficacy, 66% of patients achieved IGA success in their scalp psoriasis (search), and 40% achieved a clear scalp. These benefits, combined with itch reduction, translate to an improved quality of life for patients due to the product's ease of use.
Roflumilast foam 0.3% is a non-steroidal, once-per-day phosphodiesterase-4 (PDE4 (search)) inhibitor. The ARRECTOR trial's results suggest that it represents a valuable addition to the psoriasis (search) treatment landscape, offering a well-tolerated and effective option for patients seeking relief from itch and improved overall well-being.